|
Volume 15, Issue 2 (March 2013) 15, 218–220; 10.1038/aja.2012.130
Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer
Hui-Jie Jia1,2, Yang Li1, Jin-Guo Wang1, Ling Zhang1, Hai-Tao Zhang3, Xue-Jian Zhao1 and Masaaki Kuwahara4
1 Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Centre, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China
2 Laboratory of Transplantation and Immunology, Xuzhou Medical College, Xuzhou 221000, China
3 Department of Pathology and Laboratory Medicine, and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA
4 Sendai Reno-Urological Clinic, 3-1-32 Minami-yoshinari, Sendai 9893204, Japan
Correspondence: Dr XJ Zhao, (zhaoxuejian2007@yahoo.com.cn); Dr M Kuwahara, (adataranzk171@yahoo.co.jp)
| Abstract |
|
The PSA screening for 25 years in America is the biggest cohort study in a field of public health.27 We should realize not only the significance of the early diagnosis and treatment of PCa, but also the dramatic decrease in PCaMR from 2002 to 2008. The data from the IARC were especially noteworthy.Moreover, the patients with highly aggressive PCa, who account for more than 30% of all PCa patients, could only be diagnosed earlier by PSA screening. The patients would thus gain the opportunity for earlier treatment and would have a prolonged, higher quality life-span. However, the complications of interventional treatments, including biopsy,radical prostatectomy and/or radiation therapy,will become more avoidable in the near future.According to the supporting evidence for the decrease in PCa mortality in PSA screening, we strongly hope that the USPSTF changes the 'D' recommendation for PSA screening.
PDF |
PDF |
中文摘要 |
|
| |
| Browse: 4191 |
|
